07 December 2023>: Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz 1ACDEF* , Anna Dańska-Bidzińska 2ABDEG , Małgorzata Fuksiewicz 1BCDE , Anna Nasierowska-Guttmejer 3BC , Dorota Raczkiewicz 4C , Mariusz Gujski 5BEF , Szymon Piątek 6B , Mariusz Bidziński 6AEGDOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 2 Comparison of FIGO stage (2009) with histological types of sarcomas.
Histopathology | Stage IA | Stage IB | Stage IIA | Stage IIB | Stage IIIA |
---|---|---|---|---|---|
Carcinosarcoma | 9 (50%) | 8 (44%) | 1 (6%) | ||
Leiomyosarcoma | 2 (15%) | 5 (38%) | 3 (23%) | 3 (23%) | |
ESS high grade | 3 (30%) | 5 (50%) | 1 (10%) | 1 (10%) | |
ESS low grade | 2 (50%) | 2 (50%) | |||
Adenosarcoma | 4 (80%) | 1 (20%) | |||
Rhabdomyosarcoma | 1 (100%) | ||||
Solitary malignant fibrous tumour | 1 (100%) |